Phillips-Medisize said today that it plans to open an 80,000 square foot drug delivery manufacturing facility at its Menomonie, Wisconsin campus. The facility, which is expected to open in 2017, will manufacture high volume, prefilled drug delivery systems. It will employ at least 100 people, the company said, and is funded by the signing of a new supply contract with an undisclosed biopharmaceutical company.
The site’s expansion is the latest in a series over the past 4 years. Last November, Phillips-Medisize doubled the size of its New Richmond, Wisconsin medical device facility and earlier this year, the company opened a 17,000 square foot clinical and pilot build facility for drug delivery combination products in Menomonie, Wisconsin.
“This expansion illustrates our continued commitment and investment in the design and manufacturing of drug delivery devices for biopharmaceutical companies, globally. Expanding in Menomonie adds to our manufacturing capacity to produce fully assembled and packaged drug delivery devices,” president & CEO Matt Jennings said in prepared remarks. “We are proud of this leading-edge manufacturing campus featuring advanced molding and assembly, cold-chain drug handling, serialization technologies and FDA-registered dedicated clinical and pilot build facilities for drug delivery and finished combination products.”
“The recent acquisition of Phillips-Medisize by Molex bolsters our ability to provide comprehensive end-to-end electronics solutions as part of our drug delivery device capabilities. Customer response to our addition of Molex electronics capabilities has been tremendous,” Jennings added.
